mRNA Vaccine Technology
Aug 26, 2026
From COVID-19 to Seasonal Influenza: Is mRNA Vaccine Technology Entering Its Second Act?
In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna's own count, the company's fourth approved U.S. prod...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
